ZANTE GREG

CFO Greg Zante sells 57,661 shares of VKTX for $1,896,969.39 on 2026-01-05; 5 of 5 prior VKTX sales well-timed with negative 90-day returns averaging -51.6%.

On 2026-01-05, Greg Zante (CFO) executed four separate sales totaling 57,661 shares for $1,896,969.39, reducing his holdings by 23.3% to 189,891 shares at a blended average price of $32.90. His prior trade history at VKTX is notably consistent: all five prior sales achieved well-timed exits, with 90-day average returns of -51.6% (ranging from -47.0% to -55.2%), indicating the stock declined meaningfully after each prior sale. The company is unprofitable ($-90,787,000.00 net income) with zero revenue in the latest quarter and a $3.6B market cap, providing fundamental context for a CFO's large discretionary sale. The current stock price ($32.14) is -25.1% from its 52-week high of $42.89 and down -16.6% over 30 days, positioning this sale in an already-declining price environment where the insider's decision to liquidate a meaningful fraction of holdings merits investor scrutiny.

CFO Greg Zante sells 50,309 shares at blended $42.75; stock down -55.0% from 52-week high of $94.50.

Greg Zante, CFO of Viking Therapeutics (VKTX), executed 2 separate sales totaling 50,309 shares for $2,150,594.66 on 2025-01-06 at an average price of $42.75. The sale represents a -23.3% reduction of his post-transaction holdings (165,259 shares remain). The stock currently trades at $42.53, down -55.0% from its 52-week high of $94.50 and -36.2% over the past 90 days, suggesting this sale occurred during a sustained downtrend. At the same-ticker level, Zante's five prior sells at VKTX (all on 2024-10-28) each showed negative 30-day returns ranging from -26.9% to -33.1%, indicating his recent selling activity has coincided with further declines. The company reported zero revenue in the latest quarter and a net loss of $24,940,000, underscoring fundamental operational challenges that investors should monitor.

CFO ZANTE GREG sells 131.7K shares for $10.1M across 8 transactions on 2024-10-28; stock down 21.1% from 52-week high.

ZANTE GREG, CFO of Viking Therapeutics, executed 8 separate sales totaling 131,687 shares for $10,089,164.07 on 2024-10-28, reducing his holdings by 46.9% from 281,053 to 149,366 shares. The blended average price of $76.61 reflects transaction prices ranging from $74.56 to $81.44—notably above the current price of $74.52. The size and urgency of this divestiture (liquidating nearly half his position) during a 30-day window showing +20.9% gains and a 90-day window showing +31.8% gains merits scrutiny. Critically, the company is unprofitable with net income of $-24,940,000.00 and revenue of $0.00 in the latest quarter, while the stock trades -21.1% from its 52-week high of $94.50, indicating significant recent volatility. His prior trading history at VKTX shows 2 of 5 prior sells were well-timed at the 90-day mark, but the current divestiture occurs at elevated prices after substantial recent appreciation, warranting monitoring of whether this reflects a shift in confidence at the executive level.

CFO Greg Zante sells 16,136 shares at $57.15 avg for $922.2K; stock down -39.7% from 52-week high.

Greg Zante, CFO of Viking Therapeutics, executed 3 separate sales totaling 16,136 shares for $922,212.06 on 2024-07-30 at prices between $56.96 and $58.71, reducing his holdings by 7.9% to 187,052 shares. The timing warrants attention: the company is unprofitable with net income of $-22,250,000.00 and zero revenue in the latest quarter, while the stock has declined 39.7% from its 52-week high of $94.50 and lost 24.8% over the prior 90 days. Zante's prior transactions at Viking show a consistent pattern—four prior May 2024 sells all recorded negative 30-day returns ranging from -15.3% to -18.2%—yet he has continued to sell at this ticker despite measurable post-transaction declines. The current sale at $57.00 (current price) sits below transaction prices, but the broader context of ongoing sales into a deteriorating stock price and deteriorating fundamentals in an unprofitable company suggests continued insider liquidation rather than confidence in near-term recovery.